SPECIAL FEATURE - PFS & Parenteral Delivery: Innovation Is Focused on Patient-Centric, Smart & Sustainable Solutions
Contributor Cindy H. Dubin speaks with several innovating companies to discuss trends in PFS as well as advancements in autoinjectors and innovations in parenteral delivery.
TRANSDERMAL DELIVERY - SkinJect’s Doxorubicin-Loaded Dissolvable Microneedle Array (D-MNA): A Revolutionary Approach to Transdermal Drug Delivery
Raza Bokhari, MD, Edward Brennan, MD, FACS, and Madison Weisz, MS, explore the D-MNA treatment, highlighting its drug delivery mechanisms, advantages over traditional treatments, and clinical potential.
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
FORMULATION FORUM - Self-Emulsifying Drug Delivery Systems for Improving Oral Bioavailability of Drugs
Jim Huang, PhD, and Shaukat Ali, PhD, say as more NCEs continue to be discovered with less options to find the appropriate excipients and solubilizers for Class II and IV drugs, the pharma industry has begun to evaluate liquid SEDDS for expediting drugs to market.
EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
NASAL DRUG DELIVERY - Overcoming the Challenges of Formulation Development
Eric Kaneps explores the nasal drug delivery landscape, including the benefits of nasal administration compared with other routes and the unique formulation challenges associated with this delivery method.
EXECUTIVE INTERVIEW - Salipro Biotech & Bio-Rad Laboratories: A Powerful Solution for Antibody Discovery Against Challenging Transmembrane Targets
Dr. Jens Frauenfeld, CEO, Salipro Biotech, and Dr. Francisco Ylera, R&D Team Lead at Bio-Rad Laboratories, explain how their collaboration is leveraging the Salipro® platform alongside Bio-Rad’s Pioneer™ Antibody Discovery Platform to target transmembrane proteins.
THERAPEUTIC FOCUS - Targeting Chronic Inflammation in Obesity
Johnny Peppers, PhD, and Christopher Mojcik, MD, PhD, explore the connection of obesity and inflammation, the current treatment landscape, and directions for future treatment.
DRUG DEVELOPMENT - The Next Frontier in Immunotherapy for Ovarian Cancer
Khursheed Anwer, PhD, MBA, and Douglas V. Faller, MD, PhD, highlight a new delivery system (TheraPlas®) being used to develop a more localized IL-12 immunotherapy for ovarian cancer and review its promising Phase 2 results.
EXECUTIVE INTERVIEW - Gelteq: A Breakthrough Ingestible Gel Drug & Nutrient Delivery System
Nathan Givoni, Co-Founder and CEO of Gelteq, discusses challenges with traditional drug delivery and the company’s innovative ingestible gel platform designed for drug and nutrient delivery.
CONTRACT SERVICES - When Choosing Stent, Catheter & Tubing Partners, Less is More
Andrew Filachek says the ability to combine ideation and early stage development with materials science and process technologies has, in recent years, become a differentiator across a variety of device categories.
EXECUTIVE INTERVIEW - MediWound Ltd.: Developing a New Class of Biologic Enzymatic Therapeutic Products to Debride Wounds
Ofer Gonen, Chief Executive Officer of MediWound, discusses the company’s innovative approach to debridement.
ADC PAYLOADS - Progress in Development of Camptothecin-Based ADC Therapeutics
Paul Moore, PhD, Raffaele Colombo, PhD, and Jamie Rich, PhD, say the recent progress in research on novel camptothecin payloads highlights the potential for developing a new generation of ADCs that can overcome some of the limitations of first-generation therapies.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Ionizable Lipids in LNPs: A Selection Guide
Finding the right ionizable lipid is critical for optimal formulations. This guide helps navigate the wide range of ionizable lipids for specific therapeutic needs. Explore lipids by target or cargo type.
How to Choose the Right CDMO for Your Pharmaceutical Project
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
Understanding the Foundation of LNP Formulation Success
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
Lyophilization Development: Quality by Design Approach
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
Choosing the Right Particle for Your Nanomedicine Application
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
WHITEPAPER: Partnering With Gattefossé to Tackle Veterinary Medicine Challenges
Veterinary medicines face unique challenges due to species diversity, physiology, and dosing needs. Animals can’t be instructed to take medicine, so palatability, safety, and bioavailability…
WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations
By overcoming key challenges 3D screen printing is unlocking new possibilities in drug development and manufacturing.
WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide
Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug…
CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form
In this CPHI Award-winning case study, learn how Adare scientists took the alternative sprinkle version out of the lab and into the hands of patients.
ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products
Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs.
EXCLUSIVE WEBINARS
WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
WEBINAR - ABISOL Emulsion Preconcentrate Kit & ABISORB-DC Excipient System for Tableting Lipids
ABITEC Technical Business Director, John Tillotson, RPh, PhD, discusses ABITEC’s latest products: The ABISOL Emulsion Preconcentrate kit for the easy formulation of emulsified drug delivery systems and the….
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
MARKET NEWS & TRENDS
Lonza Launches Design2Optimize Platform to Streamline API Development
Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), announced today the launch of its new Design2Optimize platform to enhance process development…
Sanofi to Acquire Vigil Neuroscience, Adding a New Investigational Medicine to Treat Alzheimer’s Disease
Sanofi recently announced it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies…
Amphista Therapeutics Showcases Cryo-EM Enabled Platform for Discovering Novel Targeted Glue Degraders
Amphista Therapeutics presented its unique approach to constructing novel, orally bioavailable Targeted Glue protein degraders with mechanisms of action (MoA) distinct from traditional CRBN/VHL approaches…
Belite Bio Announces Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
Belite Bio, Inc. recently announced the US FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the…
Kaida BioPharma Announces New Partnership With Northway Biotech for the Manufacturing of KAD101
Kaida BioPharma recently announced it has entered into a manufacturing agreement with Northway Biotech, Inc. for the manufacturing of lead product candidate, KAD101. Under the…
Montara Therapeutics to Develop Novel Treatments Using the BrainOnly Platform
Montara Therapeutics recently announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in addition to joining MJFF’s…
Philikos Announces Initiation of Clinical Phase 1/2 Study With T-Guard in Patients With Systemic Sclerosis
Philikos B.V. recently announced it has enrolled the first patient in a Phase 1/2 clinical trial designed to evaluate the use of T-Guard for the…
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for…
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing & Evidence of Early Immune Activation Signals
GT Biopharma, Inc. recently announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation…
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates With Novel Cyclic Peptides
FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed…
SISCAPA & Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions
SISCAPA Assay Technologies and Biognosys recently announced an exclusive strategic collaboration to offer biopharma customers a streamlined end-to-end solution for high-sensitivity protein analysis—from early protein…
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of an Investigational Prime Editor for Chronic Granulomatous Disease
Prime Medicine, Inc. recently announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous…
Rani Therapeutics Announces Research Agreement With Chugai
Rani Therapeutics Holdings, Inc. recently announced it has entered into a Research Agreement on August 13, 2024, for two molecules with undisclosed targets provided by…
Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy
Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced the formation of its Scientific Advisory Board (SAB) composed of…
Prolific Machines Appoints Former Catalent CSO to Board
Prolific Machines, the Photomolecular platform leader, recently announced the appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent…
Cybin Engages Thermo Fisher Scientific to Provide US-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
Cybin Inc. recently announced it has engaged Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, the company’s…
Record-Breaking FDA Biosimilar Approvals to Create Opportunities for Drug Developers & Manufacturers
FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. This presents a golden opportunity for…
Hovione & Firstgene Announce Strategic Collaboration to Advance Virus-Like Particle Platform for Liver Cancer
Hovione and Firstgene Life Sciences recently announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular…
Septerna & Novo Nordisk to Collaborate on Oral Small Molecule Medicines for Obesity & Other Cardiometabolic Diseases
Septerna, Inc. and Novo Nordisk recently announced an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small molecule medicines for obesity,…
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager for Autoimmune Disease
IN8bio, Inc. recently announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The data…
